NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.80 +0.32 (+0.41%) GOLD FUTURES
2,325.20 -6.00 (-0.26%) DOW
38,869.92 +17.65 (+0.05%) Bitcoin GBP
50,645.95 +142.43 (+0.28%)
Beam Therapeutics Inc. (BEAM)
| Previous close | 22.78 |
| Open | 22.76 |
| Bid | 22.47 x 100 |
| Ask | 22.56 x 100 |
| Day's range | 21.67 - 22.93 |
| 52-week range | 16.95 - 49.50 |
| Volume | |
| Avg. volume | 1,528,919 |
| Market cap | 1.855B |
| Beta (5Y monthly) | 1.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities;
- GlobeNewswire
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with
- GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference, emerging genetic therapy approaches corporate panel discussion on Wednesday, March 6, 2024 at 12:50 p.m. ETLeerink Partners Global Biopharma Conference, fireside chat on Monday, Marc
